Multi-omics analysis of pediatric minimally differentiated acute myeloid leukemia reveals RUNX1-driven stemness and chemoresistance
Open Access
- 29 April 2026
- journal article
- Published by Springer Nature in Leukemia
- Vol. 40 (7) , 1427-1438
Abstract
Minimally differentiated acute myeloid leukemia (AML-M0) is a rare and therapeutically challenging subgroup of AML characterized by immature hematopoietic stem cell-like features. To uncover the molecular basis, we conducted a comprehensive multi-omics analysis of 23 pediatric AML-M0 cases and compared them with 1483 leukemia samples. AML-M0 formed a characteristic group that exhibited global DNA hypermethylation and transcriptional suppression, particularly downregulation of genes related to oxidative phosphorylation and ribosome assembly compared to non-M0 AML. Genomic profiling revealed frequent loss-of-function alterations in RUNX1 (26%) and ETV6 (22%), along with activating mutations in signaling pathways (83%), such as RAS , FLT3 , and JAK . Notably, RUNX1 alterations were significantly associated with a poor prognosis. Functional analyses using a CRISPR/Cas9-mediated RUNX1 knockout in a pediatric AML-M0 cell line showed stem cell-like transcriptional features and reduced expression of genes related to oxidative phosphorylation and ribosomal pathways. RUNX1 disruption was also associated with reduced in vitro sensitivity to multiple drugs, including cytarabine and anthracyclines. Our study provides the most comprehensive molecular characterization of pediatric AML-M0 to date and identifies RUNX1 alterations as important biological and clinical determinants. These insights highlight the potential strategies for precision therapy, including hypomethylating agents, signaling inhibitors, and metabolic targeting, to improve outcomes.Keywords
Funding Information
- Japan Society for the Promotion of Science (JP20K16923 and JP24K10953)
- Japan Society for the Promotion of Science (JP18K19467, JP20H00528, JP21K19405, JP23K18264, JP24H00628, and JP25K22609)
- Masato Kawano Memorial Public Interest Foundation for Promotion of Pediatrics
- Japan Agency for Medical Research and Development (JP19cm0106509, JP22ana221505, JP23ama221505, JP24ama221531, JP25ama221531, and JP19ck0106468)
This publication has 59 references indexed in Scilit:
- Molecular signatures database (MSigDB) 3.0Bioinformatics, 2011
- ConsensusClusterPlus: a class discovery tool with confidence assessments and item trackingBioinformatics, 2010
- AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterationsBlood, 2009
- Genome wide molecular analysis of minimally differentiated acute myeloid leukemiaHaematologica, 2009
- ETV6 mutations and loss in AML-M0Leukemia, 2008
- Minimally differentiated acute myeloid leukemia (FAB AML-M0) is associated with an adverse outcome in children: a report from the Children's Oncology Group, studies CCG-2891 and CCG-2961Blood, 2006
- Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profilesProceedings of the National Academy of Sciences of the United States of America, 2005
- Analysis of treatment failure in patients with minimally differentiated acute myeloid leukemia (AML-M0).1994
- Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML‐MO)British Journal of Haematology, 1991
- MINIMALLY DIFFERENTIATED ACUTE NONLYMPHOCYTIC LEUKEMIA - A DISTINCT ENTITY1987